RP
Insider
Ra Capital Management, L.P.
DirectorRa Capital Management, L.P. (Director) filed 31 Form 4 reports as a reporting entity in the trailing twelve months (23 purchases, 8 sales, 1 filed past the two-business-day deadline), most often in Artiva Biotherapeutics, Inc. (ARTV). Across 22 priced purchase filings, the average 21-session return was +16.2% from execution and +14.2% from disclosure (delay-adjusted; derived). The largest single filing was $423.8M of PBLS (21,188,750 sh across 2 lots, as filed), executed Jun 11. Data as of Nov 8 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
+16.2%
avg across 22 priced filings
Delay-adjustediThe same average, entered at disclosure dates
+14.2%
same 22 filings, from disclosure
Filings, ttm
31
23 buys · 8 sells · 1 late
Median delay
4d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$871.5M
shares × price, as filed
Last traded
Nov 2
Filed Nov 3
Median ADV $10.0M across their filed names
Impact on $10,000 · 12M
$25,798 (+158.0%)
S&P 500 $10,907 (+9.1%) · 148.9 pts ahead
Ra Capital Management, L.P.
S&P 500
Derived: compounded across filings from disclosure dates · past 12 months
Open performance→Volume by month
Buys $856.6M
Sells $128.1M
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
25 filings
Not on file
5 filings
Sector per market data · by filing · past 12 months
Most traded names
ARTVRecent filings
WVEPURCHASE
Wave Life Sciences Ltd.
View filing →
$54.6M8,772,496 sh across 4 lots
Exec Mar 26
Filed Mar 30 · 8:30 PM ET BCAXPURCHASE Bicara Therapeutics Inc. View filing → $4.8M
300,000 sh × $16.00
Exec Feb 26
Filed Mar 2 · 4:22 PM ET ACETPURCHASE Adicet Bio, Inc. View filing → $1.6M
223,596 sh across 3 lots
Exec Feb 18
Filed Apr 13 · 5:20 PM ET † SGPPURCHASE SpyGlass Pharma, Inc. View filing → $59.0M
3,690,000 sh across 2 lots
Exec Feb 9
Filed Feb 11 · 5:15 PM ET